Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: Involvement of nitric oxide

European Neuropsychopharmacology

Volumn 23, Issue 12, 2013, Pages 1769-1778

  Pereira, Vitor S ^a   Casarotto, Plinio C ^a   Hiroaki Sato, Vinícius A ^a   Sartim, Ariandra G ^b   Guimarães, Francisco S ^a   Joca, Sâmia R L ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Department of Clinical Analysis   (Brazil)

Author keywords

Forced swimming test; Marble burying; P2 receptor; PPADS; Purinergic system

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DIAZEPAM; GLUTAMIC ACID; IMIPRAMINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PAROXETINE; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; PYRIDOXALPHOSPHATE 6 AZOPHENYL 2',5' DISULFONIC ACID TETRASODIUM SALT; UNCLASSIFIED DRUG;

ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; BRAIN REGION; CORPUS STRIATUM; DISEASE ASSOCIATION; DRUG EFFECT; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILITY; IMMUNOPRECIPITATION; MALE; MARBLE BURYING TEST; MAZE TEST; MOOD DISORDER; MOUSE; NEUROBIOLOGY; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; STRESS; SYNTHESIS;

FORCED SWIMMING TEST; MARBLE BURYING; P2 RECEPTOR; PPADS; PURINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; COMPULSIVE BEHAVIOR; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; MALE; MAZE LEARNING; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PAROXETINE; PURINERGIC ANTAGONISTS; PYRIDOXAL PHOSPHATE; RATS; RECEPTORS, PURINERGIC; SWIMMING;

EID: 84887609567     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.01.008     Document Type: Article

References (75)

1. Abbracchio M.P., Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors?. Pharmacol. Ther. 1994, 64:445-475.
2. Abel E.L., Bilitzke P.J. A possible alarm substance in the forced swimming test. Physiol. Behav. 1990, 48:233-239.
3. Aboujaoude E., Barry J.J., Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J. Clin. Psychopharmacol. 2009, 29:51-55.
4. Andersen S.L., Greene-Colozzi E.A., Sonntag K.C. A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals. Biol. Psychiatry 2010, 68:741-747.
5. Basso A.M., Bratcher N.A., Harris R.R., et al. Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: relevance for neuropsychiatric disorders. Behav. Brain Res. 2009, 198:83-90.
6. Beijamini V., Skalisz L.L., Joca S.R., et al. The effect of oxcarbazepine on behavioural despair and learned helplessness. Eur. J. Pharmacol. 1998, 347:23-27.
7. Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
8. Bernardino L., Balosso S., Ravizza T., et al. Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: a crucial role of P2X7 receptor-mediated IL-1beta release. J. Neurochem. 2008, 106:271-280.
9. Boucher A.A., Arnold J.C., Hunt G.E., et al. Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 2011, 189:170-177.
10. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol. Rev. 2006, 58:58-86.
11. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007, 87:659-797.
12. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat. Rev. Drug Discov. 2008, 7:575-590.
13. Burnstock G., Fredholm B.B., Verkhratsky A. Adenosine and ATP receptors in the brain. Curr. Top. Med. Chem. 2011, 11:973-1011.
14. Burnstock G., Krügel U., Abbracchio M.P., et al. Purinergic signalling: from normal behaviour to pathological brain function. Prog. Neurobiol. 2011, 95:229-274.
15. Butt A.M. ATP: a ubiquitous gliotransmitter integrating neuron-glial networks. Semin. Cell Dev. Biol. 2011, 22:205-213.
16. Carobrez A.P., Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci. Biobehav. Rev. 2005, 29:1193-1205.
17. Chiang H.T., Cheng W.H., Lu P.J., et al. Neuronal nitric oxide synthase activation is involved in insulin-mediated cardiovascular effects in the nucleus tractus solitarii of rats. Neuroscience 2009, 159:727-734.
18. Cho J.H., Choi I.S., Jang I.S. P2X7 receptors enhance glutamate release in hippocampal hilar neurons. Neuroreport 2010, 21:865-870.
19. Cortese B.M., Phan K.L. The role of glutamate in anxiety and related disorders. CNS Spectr. 2005, 10:820-830.
20. Czeh B., Perez-Cruz C., Fuchs E., et al. Chronic stress-induced cellular changes in the medial prefrontal cortex and their potential clinical implications: does hemisphere location matter?. Behav. Brain Res. 2008, 190:1-13.
21. Díaz-Hernandez M., del Puerto A., Díaz-Hernandez I., et al. Inhibition of the ATP-gated P2X7 receptor promotes axonal growth and branching in cultured hippocampal neurons. J. Cell Sci. 2008, 121:3717-3728.
22. Donato J., Frazao R., Fukuda M., et al. Leptin induces phosphorylation of neuronal nitric oxide synthase in defined hypothalamic neurons. Endocrinology 2010, 151:5415-5427.
23. Egashira N., Okuno R., Harada S., et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur. J. Pharmacol. 2008, 586:164-170.
24. Florenzano F., Viscomi M.T., Amadio S., et al. Do ATP and NO interact in the CNS?. Prog. Neurobiol. 2008, 84:40-56.
25. Forestiero D., Manfrim C.M., Guimaraes F.S., et al. Anxiolytic-like effects induced by nitric oxide synthase inhibitors microinjected into the medial amygdala of rats. Psychopharmacology 2006, 184:166-172.
26. Garthwaite J., Garthwaite G., Palmer R.M., et al. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur. J. Pharmacol. 1989, 172:413-416.
27. Garzon J., Rodriguez-Munoz M., Vicente-Sanchez A., et al. RGSZ2 binds to the neural nitric oxide synthase PDZ domain to regulate mu-opioid receptor-mediated potentiation of the N-methyl-d-aspartate receptor-calmodulin-dependent protein kinase II pathway. Antioxid. Redox Signal. 2011, 15:873-887.
28. Graeff F.G., Zangrossi H. The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10:207-217.
29. Grant P., Lougee L., Hirschtritt M., et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2007, 17:761-767.
30. Harmer C.J., Goodwin G.M., Cowen P.J. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br. J. Psychiatry 2009, 195:102-108.
31. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur. Psychiatry 2002, 17(Suppl. 3):S294-S299.
32. Iijima M., Kurosu S., Chaki S. Effects of agents targeting glutamatergic systems on marble-burying behavior. Neurosci. Lett. 2010, 471:63-65.
33. Inoue K., Nakazawa K., Fujimori K., et al. Extracellular adenosine 5'-triphosphate-evoked glutamate release in cultured hippocampal neurons. Neurosci. Lett. 1992, 134:215-218.
34. Inoue K. The functions of ATP receptors in hippocampus. Pharm. Res. 1998, 38:323-331.
35. Ishizuka Y., Ishida Y., Jin Q., et al. Differential profiles of nitric oxide and norepinephrine releases in the paraventricular nucleus region in response to mild footshock in rats. Brain Res. 2000, 862:17-25.
36. 2+ signalling in glial cell pathology in the central nervous system. Eur. J. Pharmacol. 2002, 447:247-260.
37. Jefferys D., Funder J. Nitric oxide modulates retention of immobility in the forced swimming test in rats. Eur. J. Pharmacol. 1996, 295:131-135.
38. Joca S.R., Guimaraes F.S. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology 2006, 185:298-305.
39. Khakh B.S. ATP-gated P2X receptors on excitatory nerve terminals onto interneurons initiate a form of asynchronous glutamate release. Neuropharmacology 2009, 56:216-222.
40. Khakh B.S., Henderson G. ATP receptor-mediated enhancement of fast excitatory neurotransmitter release in the brain. Mol. Pharmacol. 1998, 54:372-378.
41. Khakh B.S., North R.A. P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006, 442:527-532.
42. Kittner H., Franke H., Fischer W., et al. Stimulation of P2Y1 receptors causes anxiolytic-like effects in the rat elevated plus-maze: implications for the involvement of P2Y1 receptor-mediated nitric oxide production. Neuropsychopharmacology 2003, 28:435-444.
43. Krass M., Runkorg K., Wegener G., et al. Nitric oxide is involved in the regulation of marble-burying behavior. Neurosci. Lett. 2010, 480:55-58.
44. Krugel U., Schraft T., Regenthal R., et al. Purinergic modulation of extracellular glutamate levels in the nucleus accumbens in vivo. Int. J. Dev. Neurosci. 2004, 22:565-570.
45. Li N., Lee B., Liu R.J., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
46. Machado-Vieira R., Ibrahim L., Henter I.D., et al. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol. Biochem. Behav. 2012, 100:678-687.
47. McArthur R., Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol. Biochem. Behav. 2006, 84:436-452.
48. Miller C.M., Boulter N.R., Fuller S.J., et al. The role of the P2X(7) receptor in infectious diseases. PLoS Pathog. 2011, 7:e1002212.
49. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J. Neurochem. 1993, 60:1650-1657.
50. Montezuma, K., Biojone, C., Lisboa, S.F., Cunha, F.Q., Guimarães, F.S., Joca, S.R., 2012. Inhibition of iNOS induces antidepressant-like effects in mice: pharmacological and genetic evidence. Neuropharmacology 62(1), 485-491.
51. Morilak D.A., Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int. J. Neuropsychopharmacol. 2004, 7:193-218.
52. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol. Biochem. Behav. 1991, 38:63-67.
53. Norenberg W., Illes P. Neuronal P2X receptors: localisation and functional properties. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:324-339.
54. North R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82:1013-1067.
55. Ohnishi T., Matsumura S., Ito S. Translocation of neuronal nitric oxide synthase to the plasma membrane by ATP is mediated by P2X and P2Yreceptors. Mol. Pain 2009, 5:40-56.
56. O'Neil M.F., Moore N.A. Animal models of depression: are there any? Hum. Psychopharmacology 2003, 18:239-254.
57. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
58. Price J.L., Drevets W.C. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010, 35:192-216.
59. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
60. Sandoval R., González A., Caviedes A., et al. Homeostatic NMDA receptor down-regulation via brain derived neurotrophic factor and nitric oxide-dependent signalling in cortical but not in hippocampal neurons. J. Neurochem. 2011, 118:760-772.
61. Shors T.J., Seib T.B., Levine S., et al. Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus. Science 1989, 244:224-226.
62. Silva M., Aguiar D.C., Diniz C.R., et al. Neuronal NOS inhibitor and conventional antidepressant drugs attenuate stress-induced fos expression in overlapping brain regions. Cell. Mol. Neurobiol. 2012, 32:443-453.
63. Simon A.B., Gorman J.M. Advances in the treatment of anxiety: targeting glutamate. NeuroRx 2006, 3:57-68.
64. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 2009, 30:563-569.
65. Spiacci A., Kanamaru F., Guimaraes F.S., et al. Nitric oxide-mediated anxiolytic-like and antidepressant-like effects in animal models of anxiety and depression. Pharmacol. Biochem. Behav. 2008, 88:247-255.
66. Stehberg, J., Moraga-Amaro, R., Salazar, C., Becerra, A., Echeverría, C., Orellana, J.A., Bultynck, G., Ponsaerts, R., Leybaert, L., Simon, F., Sáez, J.C., Retamal, M.A., 2012. Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear memory consolidation in the basolateral amygdala. FASEB J. 26(9), 3649-3657.
67. Thomas A., Burant A., Bui N., et al. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology 2009, 204:361-373.
68. Umathe S.N., Bhutada P.S., Jain N.S., et al. Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice. Nitric Oxide 2009, 21:140-147.
69. Wegener G., Harvey B.H., Bonefeld B., et al. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int. J. Neuropsychopharmacol. 2010, 13:461-473.
70. Wilson H.L., Varcoe R.W., Stokes L., et al. P2X receptor characterization and IL-1/IL-1Ra release from human endothelial cells. Br. J. Pharmacol. 2007, 151:115-127.
71. World Health Organization, 2008. The global burden of disease: 2004 update. World Health Organization, Geneva.
72. Zarate C., Machado-Vieira R., Henter I., et al. Glutamatergic modulators: the future of treating mood disorders?. Harv. Rev. Psychiatry 2010, 18:293-303.
73. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
74. Zhou Q.G., Hu Y., Hua Y., et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J. Neurochem. 2007, 103:1843-1854.
75. Zlatkovic J., Filipovic D. Bax and B-cell-lymphoma 2 mediate proapoptotic signaling following chronic isolation stress in rat brain. Neuroscience 2012, 223:238-245.